(Q38557137)

4 September 2017

0 references

1 reference

title

Efficacy of Ginkgo biloba extract EGb 761(®) in dementia with behavioural and psychological symptoms: A systematic review (English)

1 reference

4 September 2017

0 references

1 reference

1

Armin von Gunten

0 references

author name string

Armin von Gunten

series ordinal

1

1 reference

4 September 2017

Sandra Schlaefke

series ordinal

2

1 reference

4 September 2017

Karl Überla

series ordinal

3

1 reference

4 September 2017

publication date

30 July 2015

1 reference

World Journal of Biological Psychiatry

4 September 2017

published in

1 reference

4 September 2017

volume

17

1 reference

4 September 2017

issue

8

1 reference

4 September 2017

page(s)

622-633

1 reference

What do we know about quality of life in dementia? A review of the emerging evidence on the predictive and explanatory value of disease specific measures of health related quality of life in people with dementia

4 September 2017

cites work

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2015.1066513

The short- and long-term effect of duloxetine on painful physical symptoms in patients with generalized anxiety disorder: results from three clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2015.1066513

Ginkgo biloba for cognitive impairment and dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2015.1066513

The Gottfries-Bråne-Steen scale: validity, reliability and application in anti-dementia drug trials

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2015.1066513

The Neuropsychiatric Inventory: assessing psychopathology in dementia patients

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2015.1066513

Improvement in behavioural symptoms in patients with moderate to severe Alzheimer's disease by memantine: a pooled data analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2015.1066513

Influence of behavioral symptoms on rates of institutionalization for persons with Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2015.1066513

A rating scale for depression

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2015.1066513

Ginkgo biloba extract EGb 761® in dementia with neuropsychiatric features: a randomised, placebo-controlled trial to confirm the efficacy and safety of a daily dose of 240 mg.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2015.1066513

Meta-analysis of continuous outcome data from individual patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2015.1066513

Neuropsychometric tests in cross sectional and longitudinal studies - a regression analysis of ADAS - cog, SKT and MMSE.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2015.1066513

Baseline neuropsychiatric symptoms are effect modifiers in Ginkgo biloba extract (EGb 761®) treatment of dementia with neuropsychiatric features. Retrospective data analyses of a randomized controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2015.1066513

World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of Alzheimer's disease and other dementias

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2015.1066513

Ginkgo biloba in Alzheimer's disease: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2015.1066513

Ginkgo biloba extract EGb 761 in dementia: intent-to-treat analyses of a 24-week, multi-center, double-blind, placebo-controlled, randomized trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2015.1066513

Neuropsychiatric symptoms and quality of life in patients with very mild and mild Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2015.1066513

Factor structure and scoring of the SKT test battery.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2015.1066513

A 26-week analysis of a double-blind, placebo-controlled trial of the ginkgo biloba extract EGb 761 in dementia.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2015.1066513

How useful are cholinesterase inhibitors in the treatment of Alzheimer's disease? A number needed to treat analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2015.1066513

The efficacy of licensed-indication use of donepezil and memantine monotherapies for treating behavioural and psychological symptoms of dementia in patients with Alzheimer's disease: systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2015.1066513

Mental and behavioral disturbances in dementia: findings from the Cache County Study on Memory in Aging

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2015.1066513

The TE4D-Cog: a new test for detecting early dementia in English-speaking populations.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2015.1066513

Epidemiological pathology of dementia: attributable-risks at death in the Medical Research Council Cognitive Function and Ageing Study

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2015.1066513

Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2015.1066513

The spectrum of behavioral responses to cholinesterase inhibitor therapy in Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2015.1066513

Effects of the standardized Ginkgo biloba extract EGb 761® on neuroplasticity

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2015.1066513

Clustering of behavioural and psychological symptoms in dementia (BPSD): a European Alzheimer's disease consortium (EADC) study.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2015.1066513

Absence of effect of depression on cognitive performance in early-stage Alzheimer disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2015.1066513

Predictors of progression to severe Alzheimer's disease in an incidence sample

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2015.1066513

Are cholinesterase inhibitors effective in the management of the behavioral and psychological symptoms of dementia in Alzheimer's disease? A systematic review of randomized, placebo-controlled trials of donepezil, rivastigmine and galantamine.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2015.1066513

A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Donepezil Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2015.1066513

Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2015.1066513

Eligibility of Alzheimer's disease clinic patients for clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2015.1066513

A randomized, double-blind, placebo-controlled trial of two doses of Ginkgo biloba extract in dementia of the Alzheimer's type.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2015.1066513

Mixed brain pathologies account for most dementia cases in community-dwelling older persons.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2015.1066513

Measurement of health-related quality of life for people with dementia: development of a new instrument (DEMQOL) and an evaluation of current methodology

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2015.1066513

Point and 5-year period prevalence of neuropsychiatric symptoms in dementia: the Cache County Study

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2015.1066513

Neuropsychiatric symptoms in Alzheimer disease and cognitively impaired, nondemented elderly from a community-based sample in Brazil: prevalence and relationship with dementia severity

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2015.1066513

Vascular factors and risk for neuropsychiatric symptoms in Alzheimer's disease: the Cache County Study

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2015.1066513

Behavioral symptoms in mild cognitive impairment as compared with Alzheimer's disease and healthy older adults.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2015.1066513

Effects of Ginkgo biloba in dementia: systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2015.1066513

10.3109/15622975.2015.1066513

21 January 2018

Identifiers

DOI

1 reference

4 September 2017

1 reference